Latest Period
Q1 2026
Security Snapshot
Pasithea Therapeutics Corp. - Common Stock (KTTA) Institutional Ownership
CUSIP: 70261F202
13F Institutional Holders and Ownership History from Q1 2024 to Q1 2026
Institutions Reporting
21
Shares (Excl. Options)
12,818,768
Price
$0.74
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Stock
- Symbol
- KTTA on Nasdaq
- Shares outstanding
- 25,016,593
- Price per share
- $0.69
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 12,818,768
- Total reported value
- $9,515,703
- % of total 13F portfolios
- 0%
- Share change
- -73,314
- Value change
- -$559,110
- Number of holders
- 21
- Price from insider filings
- $0.69
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Key facts
- KTTA - Pasithea Therapeutics Corp. - Common Stock is tracked under CUSIP 70261F202.
- 21 institutions reported positions in Q1 2026.
- 13 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 24 to 21 between Q4 2025 and Q1 2026.
- Reported value moved from $16,641,289 to $9,515,703.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 21 institutions filings for Q1 2026.
Security key
70261F202
Latest holder period
Q1 2026
13F holders
21
13D/G owners
13
CIK / CUSIP context first
Open Q1 2026 holders
KTTA full holder history
Pasithea Therapeutics Corp. SEC filings
Pasithea Therapeutics Corp. company facts
Pasithea Therapeutics Corp. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 70261F202:
Significant Owners of Pasithea Therapeutics Corp. - Common Stock (KTTA) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Vivo Opportunity Fund Holdings, L.P. | 10% | $12,292,327 | 17,560,467 | Vivo Opportunity Fund Holdings, L.P. | 01 Dec 2025 | |||
| JANUS HENDERSON GROUP PLC | 10% | $7,160,756 | 10,229,652 | JANUS HENDERSON GROUP PLC | 28 Nov 2025 | |||
| Opaleye Management Inc. | 10% | $2,092,440 | 2,491,000 | Opaleye Management Inc. | 01 Apr 2026 | |||
| Coastlands Capital LP | 10% | $2,059,498 | 2,394,765 | Coastlands Capital LP | 23 Feb 2026 | |||
| Adage Capital Management, L.P. | 10% | $2,050,179 | 2,329,749 | Adage Capital Management, L.P. | 31 Dec 2025 | |||
| Squadron Capital Management LLC | 9.9% | 0% | $2,050,179 | +$67,601 | 2,329,749 | +3.4% | Squadron Master Fund LP | 31 Dec 2025 |
| Funicular Funds, LP | 7.4% | $1,416,424 | 1,839,512 | Funicular Funds, LP | 15 Apr 2026 | |||
| AMERIPRISE FINANCIAL INC | 5.4% | -38% | $1,026,681 | -$440,216 | 1,350,896 | -30% | Ameriprise Financial, Inc. | 31 Mar 2026 |
| CVI Investments, Inc. | 3.8% | -61% | $791,995 | +$64,987 | 899,994 | +8.9% | CVI Investments, Inc. | 31 Dec 2025 |
| Orca Capital AG | 4.9% | -13% | $613,228 | -$14,002 | 362,857 | -2.2% | Orca Capital AG | 07 May 2025 |
| INTRACOASTAL CAPITAL, LLC | 5% | $537,188 | 317,863 | Mitchell P. Kopin | 06 May 2025 | |||
| ARMISTICE CAPITAL, LLC | 5% | -50% | $240,119 | +$14,019 | 142,082 | +6.2% | Armistice Capital, LLC | 31 Mar 2025 |
| STEINMAN LAWRENCE | 3.1% | $141,720 | 83,858 | Lawrence Steinman | 01 Mar 2025 |
As of 31 Mar 2026, 21 institutional investors reported holding 12,818,768 shares of Pasithea Therapeutics Corp. - Common Stock (KTTA). This represents 51% of the company’s total 25,016,593 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Pasithea Therapeutics Corp. - Common Stock (KTTA) together control 51% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 8.4% | 2,100,000 | 0% | 0% | $1,557,780 |
| Vivo Capital, LLC | 8.4% | 2,100,000 | 0% | 0.13% | $1,557,780 |
| JANUS HENDERSON GROUP PLC | 8.4% | 2,100,000 | 0% | 0% | $1,564,500 |
| Squadron Capital Management LLC | 8.4% | 2,100,000 | 0% | 0.62% | $1,557,780 |
| AMERIPRISE FINANCIAL INC | 5.4% | 1,350,896 | -30% | 0% | $1,002,094 |
| Cable Car Capital, LP | 4.8% | 1,206,379 | +141% | 0.31% | $894,892 |
| Stonepine Capital Management, LLC | 3.3% | 831,301 | +202% | 0.54% | $616,659 |
| AdvisorShares Investments LLC | 1.3% | 337,508 | +11% | 0.05% | $250,363 |
| Persistent Asset Partners Ltd | 1.2% | 290,555 | 0% | 0.08% | $215,534 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.42% | 103,985 | +91% | 0% | $77,138 |
| RENAISSANCE TECHNOLOGIES LLC | 0.37% | 93,399 | 0% | $69,283 | |
| VANGUARD CAPITAL MANAGEMENT LLC | 0.22% | 53,815 | 0% | 0% | $39,931 |
| VANGUARD FIDUCIARY TRUST CO | 0.18% | 43,860 | 0% | 0% | $32,544 |
| XTX Topco Ltd | 0.13% | 33,751 | +62% | 0% | $25,036 |
| UBS Group AG | 0.1% | 26,149 | +97% | 0% | $19,402 |
| TWO SIGMA INVESTMENTS, LP | 0.08% | 21,054 | -57% | 0% | $15,618 |
| NORTHERN TRUST CORP | 0.08% | 19,372 | -31% | 0% | $14,370 |
| Hurley Capital, LLC | 0.01% | 3,689 | 0% | 0% | $2,737 |
| Tower Research Capital LLC (TRC) | 0.01% | 1,854 | -37% | 0% | $1,375 |
| SBI Securities Co., Ltd. | 0% | 1,051 | 0% | 0% | $780 |
| JPMORGAN CHASE & CO | 0% | 150 | 0% | 0% | $107 |
| JANE STREET GROUP, LLC | 0% | 0 | -100% | $0 | |
| ACUTA CAPITAL PARTNERS, LLC | 0% | 0 | -100% | $0 | |
| STEMPOINT CAPITAL LP | 0% | 0 | -100% | $0 | |
| CITADEL ADVISORS LLC | 0% | 0 | -100% | $0 |
Institutional Holders of Pasithea Therapeutics Corp. - Common Stock (KTTA) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 12,818,768 | $9,515,703 | -$559,110 | $0.74 | 21 |
| 2025 Q4 | 12,892,082 | $16,641,289 | +$13,193,231 | $1.29 | 24 |
| 2025 Q3 | 612,004 | $441,403 | +$224,539 | $0.73 | 18 |
| 2025 Q2 | 300,344 | $216,624 | +$151,923 | $0.72 | 10 |
| 2025 Q1 | 78,704 | $99,102 | -$116,583 | $1.30 | 7 |
| 2024 Q4 | 77,162 | $243,273 | +$214,440 | $3.15 | 7 |
| 2024 Q3 | 9,086 | $48,891 | -$103,371 | $5.42 | 6 |
| 2024 Q2 | 29,996 | $151,569 | -$300 | $5.06 | 7 |
| 2024 Q1 | 30,055 | $218,102 | +$218,102 | $7.28 | 6 |